Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination

Horn J, Karch A, Damm O, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann O, Hengel H, Greiner W, Mikolajczyk RT (2016)
HUMAN VACCINES & IMMUNOTHERAPEUTICS 12(7): 1766-1776.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor/in
; ; ; ; ; ; ; ; ; ;
Abstract / Bemerkung
Varicella zoster virus (VZV) is primarily known for causing varicella in childhood, but can reactivate again as herpes zoster (HZ) after a period of latency, mainly in persons older than 50 years. Universal varicella vaccination was introduced in Germany in 2004, while HZ vaccination has not been recommended yet. We aimed to quantify the potential long-term effects of universal childhood varicella vaccination and HZ vaccination of the elderly on varicella and HZ incidence in Germany over a time horizon of 100 years, using a transmission model calibrated to pre-vaccination data and validated against early post-vaccination data. Using current vaccination coverage rates of 87% (64%) with one (two) varicella vaccine dose(s), the model predicts a decrease in varicella cases by 89% for the year 2015. In the long run, the incidence reduction will stabilize at about 70%. Under the assumption of the boosting hypothesis of improved HZ protection caused by exposure to VZV, the model predicts a temporary increase in HZ incidence of up to 20% for around 50 years. HZ vaccination of the elderly with an assumed coverage of 20% has only limited effects in counteracting this temporary increase in HZ incidence. However, HZ incidence is shown to decrease in the long-term by 58% as vaccinated individuals get older and finally reach age-classes with originally high HZ incidence. Despite substantial uncertainties around several key variables, the model's results provide valuable insights that support decision-making regarding national VZV vaccination strategies.
Erscheinungsjahr
Zeitschriftentitel
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Band
12
Ausgabe
7
Seite(n)
1766-1776
ISSN
eISSN
PUB-ID

Zitieren

Horn J, Karch A, Damm O, et al. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination. HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2016;12(7):1766-1776.
Horn, J., Karch, A., Damm, O., Kretzschmar, M. E., Siedler, A., Ultsch, B., Weidemann, F., et al. (2016). Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 12(7), 1766-1776. doi:10.1080/21645515.2015.1135279
Horn, J., Karch, A., Damm, O., Kretzschmar, M. E., Siedler, A., Ultsch, B., Weidemann, F., Wichmann, O., Hengel, H., Greiner, W., et al. (2016). Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination. HUMAN VACCINES & IMMUNOTHERAPEUTICS 12, 1766-1776.
Horn, J., et al., 2016. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 12(7), p 1766-1776.
J. Horn, et al., “Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination”, HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 12, 2016, pp. 1766-1776.
Horn, J., Karch, A., Damm, O., Kretzschmar, M.E., Siedler, A., Ultsch, B., Weidemann, F., Wichmann, O., Hengel, H., Greiner, W., Mikolajczyk, R.T.: Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination. HUMAN VACCINES & IMMUNOTHERAPEUTICS. 12, 1766-1776 (2016).
Horn, Johannes, Karch, Andre, Damm, Oliver, Kretzschmar, Mirjam E., Siedler, Anette, Ultsch, Bernhard, Weidemann, Felix, Wichmann, Ole, Hengel, Hartmut, Greiner, Wolfgang, and Mikolajczyk, Rafael T. “Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination”. HUMAN VACCINES & IMMUNOTHERAPEUTICS 12.7 (2016): 1766-1776.

7 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study.
Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann O, Karch A, Mikolajczyk RT., BMC Med 16(1), 2018
PMID: 29316913
Trends in herpes zoster epidemiology in Germany based on primary care sentinel surveillance data, 2005-2016.
Zoch-Lesniak B, Tolksdorf K, Siedler A., Hum Vaccin Immunother 14(7), 2018
PMID: 29498894
Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany.
Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A, Hengel H, Wichmann O, Poethko-Müller C., BMC Infect Dis 17(1), 2017
PMID: 28525973
[Protection from a dormant time bomb: The development of effective vaccines against herpes zoster].
Schelling J, Rückert-Eheberg IM, Leischker AH., MMW Fortschr Med 159(10), 2017
PMID: 28550546
Varicella vaccination - the global experience.
Wutzler P, Bonanni P, Burgess M, Gershon A, Sáfadi MA, Casabona G., Expert Rev Vaccines 16(8), 2017
PMID: 28644696
Post-herpetic neuralgia - a review of current management and future directions.
Schutzer-Weissmann J, Farquhar-Smith P., Expert Opin Pharmacother 18(16), 2017
PMID: 29025327

55 References

Daten bereitgestellt von Europe PubMed Central.

Varicella-zoster virus epidemiology--a changing scene?
Fairley CK, Miller E., J. Infect. Dis. 174 Suppl 3(), 1996
PMID: 8896538
Begründung der STIKO für eine allgemeine Varizellenimpfung
AUTHOR UNKNOWN, 2004
Pain and its persistence in herpes zoster.
Dworkin RH, Portenoy RK., Pain 67(2-3), 1996
PMID: 8951917
Impact of the routine varicella vaccination programme on varicella epidemiology in Germany
Siedler A, Arndt U., 0
THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.
HOPE-SIMPSON RE., Proc. R. Soc. Med. 58(), 1965
PMID: 14267505
Modelling the impact of immunization on the epidemiology of varicella zoster virus.
Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G., Epidemiol. Infect. 125(3), 2000
PMID: 11218215
Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia.
Gidding HF, Brisson M, Macintyre CR, Burgess MA., Aust N Z J Public Health 29(6), 2005
PMID: 16366065
The economic value of childhood varicella vaccination in France and Germany.
Coudeville L, Brunot A, Szucs TD, Dervaux B., Value Health 8(3), 2005
PMID: 15877593
Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster.
Brisson M, Melkonyan G, Drolet M, De Serres G, Thibeault R, De Wals P., Vaccine 28(19), 2010
PMID: 20199763
Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?
Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P., Vaccine 30(17), 2011
PMID: 21964056
Social contacts and mixing patterns relevant to the spread of infectious diseases.
Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, Heijne J, Sadkowska-Todys M, Rosinska M, Edmunds WJ., PLoS Med. 5(3), 2008
PMID: 18366252
Modelling the impact of varicella vaccination on varicella and zoster.
Karhunen M, Leino T, Salo H, Davidkin I, Kilpi T, Auranen K., Epidemiol. Infect. 138(4), 2009
PMID: 19796447
Hope-Simpson's progressive immunity hypothesis as a possible explanation for herpes zoster incidence data.
Guzzetta G, Poletti P, Del Fava E, Ajelli M, Scalia Tomba GP, Merler S, Manfredi P., Am. J. Epidemiol. 177(10), 2013
PMID: 23548754
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O., Eur J Health Econ 14(6), 2012
PMID: 23271349
Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.
Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, Scalia Tomba G, Lopalco P, Rizzo C, Merler S, Manfredi P., PLoS ONE 8(4), 2013
PMID: 23613740
Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.
Weinmann S, Chun C, Schmid DS, Roberts M, Vandermeer M, Riedlinger K, Bialek SR, Marin M., J. Infect. Dis. 208(11), 2013
PMID: 23922376
Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study.
Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, Lewis E, Fireman B, Saddier P., Pediatrics 131(5), 2013
PMID: 23545380
Herpes zoster in a partially vaccinated pediatric population in central Israel.
Stein M, Cohen R, Bromberg M, Tasher D, Shohat T, Somekh E., Pediatr. Infect. Dis. J. 31(9), 2012
PMID: 22627868
The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination.
Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, Seward JF., Pediatr. Infect. Dis. J. 28(11), 2009
PMID: 19536039
Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.
van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ., Vaccine 27(9), 2009
PMID: 19135492
Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O., BMC Health Serv Res 13(), 2013
PMID: 24070414
Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ., Vaccine 31(9), 2013
PMID: 23306360
Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, Stefkovicova M, Usonis V, Wysocki J, Douha M, Vassilev V, Nicholson O, Innis BL, Willems P., Lancet 383(9925), 2014
PMID: 24485548
Effectiveness of 2 doses of varicella vaccine in children.
Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, LaRussa PS, Gershon AA., J. Infect. Dis. 203(3), 2011
PMID: 21208922
Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, Chan I; Study Group for Varivax., Pediatr. Infect. Dis. J. 23(2), 2004
PMID: 14872179
Challenges to implementing second-dose varicella vaccination during an outbreak in the absence of a routine 2-dose vaccination requirement--Maine, 2006.
Parker AA, Reynolds MA, Leung J, Anderson M, Rey A, Ortega-Sanchez IR, Schmid DS, Guris D, Gensheimer KF., J. Infect. Dis. 197 Suppl 2(), 2008
PMID: 18419381
Chickenpox outbreak in a highly vaccinated school population.
Tugwell BD, Lee LE, Gillette H, Lorber EM, Hedberg K, Cieslak PR., Pediatrics 113(3 Pt 1), 2004
PMID: 14993534
The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study.
Marziano V, Poletti P, Guzzetta G, Ajelli M, Manfredi P, Merler S., Proc. Biol. Sci. 282(1804), 2015
PMID: 25761709
Mathematische Modellierung der Auswirkungen der Varizellen-Impfung auf die Inzidenz von Herpes Zoster in Deutschland
Horn J, Damm O, Kretzschmar M, Siedler A, Wichmann O, Ultsch B., 2013
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group, Arya M, Athan E, Cunningham AL, De Looze F, Seale JP, Yeo W, Goldani L, Jacob W, Luiz Neto J, dos Santos RR, Weckx L, Zerbini C, Dutz J, Ghesquiere W, Gorfinkel I, McElhaney JE, McNeil S, Powell C, Chlibek R, Smetana J, Poder A, Ahonen A, Korhonen T, Seppa I, Vesikari T, Arnou R, Beytout J, Saillard D, Dominicus R, Esen M, Plaßmann G, Schwarz T, Tyler K, Hui D, Leung E, Pellegrino A, Volpi A, Endo M, Watanabe D, Cheong HJ, Choi WS, Choo EJ, Kim YK, Lee JS, Park DW, Peck KR, Song YG, Barba-Gomez JF, de Los Santos AM, Tinoco JC, Bayas JM, Caso C, Roure JL, Via LM, Perez SN, Lopez CN, Puig-Barbera J, de la Pinta ML, Riera MT, Diez-Domingo J, Bengner M, Berglund J, Blom KB, Liu B, Pauksens K, Rombo L, Chen MF, Cheng HS, Hwang SJ, Liu CS, McNally D, Thompson A, Andrews C, Collins H, Downey H, Ervin J, Freedman M, Hoekstra J, Hull S, Levin M, Marcadis I, Rankin B, Van Cleeff M., N. Engl. J. Med. 372(22), 2015
PMID: 25916341
Seroprevalence of varicella-zoster virus in the German population.
Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A., Vaccine 20(1-2), 2001
PMID: 11567755
Zur Seroprävalenz gegen Varizella-Zoster-Virus und zur Verlässlichkeit anamnestischer Angaben
AUTHOR UNKNOWN, 2003
Herpes zoster in Germany: quantifying the burden of disease.
Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O., BMC Infect. Dis. 11(), 2011
PMID: 21679419
[Herpes zoster in Germany. A retrospective analyse of SHL data].
Schiffner-Rohe J, Jow S, Lilie HM, Koster I, Schubert I., MMW Fortschr Med 151 Suppl 4(), 2010
PMID: 21595148
GENESIS Online-Datenbank
AUTHOR UNKNOWN, 2015
Varicella vaccination coverage of children under two years of age in Germany.
Reuss AM, Feig M, Kappelmayer L, Siedler A, Eckmanns T, Poggensee G., BMC Public Health 10(), 2010
PMID: 20723217
Vaccination coverage among children in Germany estimated by analysis of health insurance claims data.
Rieck T, Feig M, Eckmanns T, Benzler J, Siedler A, Wichmann O., Hum Vaccin Immunother 10(2), 2013
PMID: 24192604
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group., N. Engl. J. Med. 352(22), 2005
PMID: 15930418
Metaanalysis of vaccine effectiveness in varicella outbreaks.
Bayer O, Heininger U, Heiligensetzer C, von Kries R., Vaccine 25(37-38), 2007
PMID: 17706845
Varicella vaccine effectiveness in the US vaccination program: a review.
Seward JF, Marin M, Vazquez M., J. Infect. Dis. 197 Suppl 2(), 2008
PMID: 18419415
Vaccination against Herpes Zoster and Postherpetic Neuralgia.
Oxman MN, Levin MJ; Shingles Prevention Study Group, Oxman MN, Arbeit RD, Barry P, Beisel C, Boardman KD, Colling CL, Davis LE, Gelb LD, Gershon AA, Hayward AR, Irwin MR, Johnson GR, Levin MJ, Peduzzi PN, Schmader KE, Simberkoff MS, Straus SE, Weinberg A, Williams HM, Annunziato P, Chan CY, Chan IS, Silber JL., J. Infect. Dis. 197 Suppl 2(), 2008
PMID: 18419402
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J., Clin. Infect. Dis. 54(7), 2012
PMID: 22291101

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 26835890
PubMed | Europe PMC

Suchen in

Google Scholar